SEC Comment Letter for Brickell Biotech, Inc. (FRTX) (CIK 0000819050) — Sep 7, 2022
Brickell Biotech, Inc. (FRTX) (CIK 0000819050)
Date: Sept. 7, 2022 · CIK: 0000819050 · Accession: 0000000000-22-009682
AI Filing Summary & Sentiment
File numbers found in text: 333-267254
Letter
United States securities and exchange commission logo September 7, 2022 Robert Brown Chief Executive Officer Brickell Biotech, Inc. 5777 Central Avenue, Suite 102 Boulder, CO 80301 Re:Brickell Biotech, Inc. Registration Statement on Form S-1 Filed September 2, 2022 File No. 333-267254 Dear Mr. Brown: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Griffin D. Foster
Show Raw Text
United States securities and exchange commission logo
September 7, 2022
Robert Brown
Chief Executive Officer
Brickell Biotech, Inc.
5777 Central Avenue, Suite 102
Boulder, CO 80301
Re:Brickell Biotech, Inc.
Registration Statement on Form S-1
Filed September 2, 2022
File No. 333-267254
Dear Mr. Brown:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Griffin D. Foster